论文部分内容阅读
目的:探讨福辛普利与比索洛尔联合治疗舒张性心力衰竭的临床疗效和用药安全性。方法:将76例舒张性心力衰竭患者随机分成两组,对照组38例接受洋地黄、利尿剂和硝酸酯类药物治疗;观察组38例在对照组治疗基础上加用福辛普利与比索洛尔联合治疗,以6周为1个疗程,疗程结束后比较两组的总有效率。结果:观察组和对照组的显效率分别为92.10%和71.05%,两组比较差异有统计学意义(P<0.05)。两组无明显不良反应病例发生。结论:福辛普利与比索洛尔联合治疗舒张性心力衰竭具有理想疗效,建议临床进一步推广应用。
Objective: To investigate the clinical efficacy and safety of combination of fosinopril and bisoprolol in the treatment of diastolic heart failure. Methods: 76 patients with diastolic heart failure were randomly divided into two groups, the control group of 38 patients received digitalis, diuretics and nitrates drugs; observation group of 38 patients in the control group based on the use of fosinopril and peso Lol combined treatment to 6 weeks for a course of treatment, after the end of the course of treatment compared the total effective rate of both groups. Results: The effective rates of the observation group and the control group were 92.10% and 71.05%, respectively, with significant difference between the two groups (P <0.05). No significant adverse reactions occurred in both groups. Conclusion: The combination of fosinopril and bisoprolol in the treatment of diastolic heart failure has an ideal curative effect, and it is recommended to further promote the clinical application.